Search
Pacira Biosciences Inc
PCRXAdd to Watchlist
26.410USD
-0.560-2.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.04BMarket Cap
209.75P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Pacira Biosciences Inc is 7.00, ranking 112 out of 155 in the Pharmaceuticals industry. The average price target is 28.00, with a high of 38.00 and a low of 23.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
29.667
Target Price
+12.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pacira Biosciences Inc
PCRX
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Pacira Biosciences Inc's expected revenue for the next quarter?
Pacira Biosciences Inc's expected revenue is 190.82M.
What is Pacira Biosciences Inc's price target?
Analysts forecast that Pacira Biosciences Inc's price target is USD 28.00, with the highest forecast at USD 38.00 and the lowest forecast at USD 23.00.
How have Pacira Biosciences IncPCRX's recent earnings per share performed?
The market expectation was USD 0.07, while Pacira Biosciences IncPCRX's earnings per share (EPS) for the previous quarter was USD 0.04. EPS for the next quarter is expected at USD 0.65.
What is the analyst rating for Pacira Biosciences Inc?
Based on the ratings of Pacira Biosciences Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.